Mon panier

Integrin alpha V beta 8

Integrin alpha V beta 8 Informations sur la molécule

Nom anglaisintegrin alpha V/beta 8Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la ciblealphavbeta8 integrin
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisintegrin alpha V/beta 8
Alias de la ciblealphavbeta8 integrin
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

Integrin alpha V beta 8Contexte de la molécule

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8Alias de la molécule

Integrin alpha V beta 8,ITGAV&ITGB8

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences IncDiabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
Details
CRB-601CRB-601Phase 2 ClinicalCorbus Pharmaceuticals Holdings Inc, Uc San FranciscoSolid tumours
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques